ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study

WESTON, Fla., March 18, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights newly published animal model data demonstrating that inflammasome inhibition attenuates obesity-associated cardiomyopathy, which has a 5-year survival rate <50%.

Read more at globenewswire.com